Switch theme
Sign up to access all valuation multiples
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
2021
44
LTM Revenue $2.8M
Last FY EBITDA -$89.7M
$179M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Tourmaline Bio has a last 12-month revenue (LTM) of $2.8M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Tourmaline Bio achieved revenue of n/a and an EBITDA of -$89.7M.
Tourmaline Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Tourmaline Bio valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.8M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $2.8M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$89.7M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$96.6M | XXX | -$89.7M | XXX | XXX | XXX |
| EBIT Margin | -3504% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$82.8M | XXX | -$73.2M | XXX | XXX | XXX |
| Net Margin | -3003% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Tourmaline Bio's stock price is $17.
Tourmaline Bio has current market cap of $428M, and EV of $179M.
See Tourmaline Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $179M | $428M | XXX | XXX | XXX | XXX | $-3.14 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Tourmaline Bio has market cap of $428M and EV of $179M.
Tourmaline Bio's trades at n/a EV/Revenue multiple, and -2.0x EV/EBITDA.
Equity research analysts estimate Tourmaline Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Tourmaline Bio has a P/E ratio of -5.2x.
See valuation multiples for Tourmaline Bio and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $428M | XXX | $428M | XXX | XXX | XXX |
| EV (current) | $179M | XXX | $179M | XXX | XXX | XXX |
| EV/Revenue | 65.0x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -2.0x | XXX | XXX | XXX |
| EV/EBIT | -1.9x | XXX | -2.0x | XXX | XXX | XXX |
| EV/Gross Profit | 65.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.2x | XXX | -5.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -2.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTourmaline Bio's last 12 month revenue growth is 142%
Tourmaline Bio's revenue per employee in the last FY averaged n/a, while opex per employee averaged $2.0M for the same period.
Tourmaline Bio's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Tourmaline Bio's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Tourmaline Bio and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 142% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tourmaline Bio acquired XXX companies to date.
Last acquisition by Tourmaline Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . Tourmaline Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Tourmaline Bio founded? | Tourmaline Bio was founded in 2021. |
| Where is Tourmaline Bio headquartered? | Tourmaline Bio is headquartered in United States of America. |
| How many employees does Tourmaline Bio have? | As of today, Tourmaline Bio has 44 employees. |
| Who is the CEO of Tourmaline Bio? | Tourmaline Bio's CEO is Dr. Sandeep C. Kulkarni, M.D.. |
| Is Tourmaline Bio publicy listed? | Yes, Tourmaline Bio is a public company listed on NAS. |
| What is the stock symbol of Tourmaline Bio? | Tourmaline Bio trades under TRML ticker. |
| When did Tourmaline Bio go public? | Tourmaline Bio went public in 2023. |
| Who are competitors of Tourmaline Bio? | Similar companies to Tourmaline Bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Tourmaline Bio? | Tourmaline Bio's current market cap is $428M |
| What is the current revenue of Tourmaline Bio? | Tourmaline Bio's last 12 months revenue is $2.8M. |
| What is the current revenue growth of Tourmaline Bio? | Tourmaline Bio revenue growth (NTM/LTM) is 142%. |
| What is the current EV/Revenue multiple of Tourmaline Bio? | Current revenue multiple of Tourmaline Bio is 65.0x. |
| Is Tourmaline Bio profitable? | Yes, Tourmaline Bio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
